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ABSTRACT 
Repeated injection of GHRH leads to a decrease in the GH response 
in normal subjects. Arginine (Arg) stimulates GH secretion by sup- 
pression of hypothalamic somatostatin. To confirm these findings, 
eight normal men were examined in a series of five settings: test 1 
(GHRHGHRH-TRH), 100 pg GHRH injected iv, followed by 100 Kg 
GHRH, iv, after 120 min and 200 pg TRH, iv, after 150 min; test 2 
(GHRWArg-TRH), like test 1, but instead of the second GHRH in- 
jection, a 30 g Arg infusion over 30 min; test 3 (GHRWGHRH-Arg- 
TRH), like test 1, but additionally a 30 g Arg infusion after 120 min; 
test 4 (GHRH-Arg-TRH), iv GHRH and Arg infusion initially, followed 
by iv TRH after 30 min; and test 5 (TRH), 200 pg TRH, iv, at 0 min. 
For statistical evaluation, the area under the GH curve (AUC) from 
O-120 min was compared with the AUC from 120-240 min. The GH 
response to the second administration of GHRH was significantly 
lower (P < 0.02) than the first increase [AUC, 0.5 2 0.1 minmg/L 
(mean + SE) us. 1.2 t 0.31. No significant differences were found 
between the GH responses to either GHRH or Arg alone (AUC, 0.9 2 
0.2 minmg/l us. 0.9 i 0.2). A larger GH increase (P < 0.02) was seen 
after GHRH-Arg compared to GHRH alone (AUC, 1.9 2 0.4 minmg/L, 
us. 1.2 + 0.3). The GH response (P < 0.02) to GHRH-Arg stimulation 
was lower after previous GHRH injection than after GHRH-Arg stim- 
ulation alone (AUC, 1.9 +- 0.4 minmg/L us. 3.5 ? 0.9). There was a 
statistically significant difference between the TRH-stimulated TSH 
response in test 4 compared to that in test 5. We could show that 
decreasing GH responses to repeated GHRH can be avoided by a 
combined stimulation with GHRWArg. These findings suggest that 
the decreased GH response to a second GHRH bolus may be partly due 
to an elevated hypothalamic somatostatin secretion, which can be 
suppressed by Arg. The lower GH response to GHRH-Arg stimulation 
after a previous GHRH bolus suggests, furthermore, that the readily 
available GH pool in the human pituitary may be limited. (J Clin 
Endocrinol Metub 81: 1994-1998, 1996) 
G H SECRETION is controlled by the hypothalamus via GHRH and its inhibitory opponent, somatostatin 
(1). Acute injection of GHRH stimulates GH secretion in 
both normal subjects (2,3) and acromegalic patients (4,5). 
Continuous GHRH infusion fails to sustain elevated GH 
levels, and pulsatile stimulation with GHRH also leads to 
decreasing GH response in normal subjects (6). It was 
suggested that two different mechanisms may be respon- 
sible for these findings; possibly, there is a limitation of 
GH release from the pituitary on short term stimulation 
with GHRH due to partial depletion of intracellular GH 
stores (7), or the stimulation of GH secretion by GHRH 
may be antagonized by somatostatin secretion from the 
hypothalamus. As the half-life of somatostatin is ex- 
tremely short (8), and somatostatin is also produced in the 
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pancreas and gut, somatostatin levels in peripheral blood 
do not reflect any fluctuations of its concentration in the 
portal circulation. Arginine (Arg) stimulates GH secretion 
by suppressing hypothalamic somatostatin (9), allowing 
indirect conclusions about the hypothalamic somatostatin 
tonus. 
The following study on Arg application was designed to 
determine whether decreases in GH release after repeated 
stimulation by GHRH are due to exhaustion of the readily 
releasable GH pool in human pituitary or whether the GH 
secretion is specifically suppressed by increasing portal lev- 
els of somatostatin. 
Materials and Methods 
We studied eight healthy men (mean age, 26.3 yr; range, 19-33), 
all of normal height, within 15% of the ideal body weight, and taking 
no medication known to interfere with GH secretion. The volunteers 
agreed to participate in the study and gave informed consent in 
written form. The men were studied in a randomized fashion in a 
series of five different settings separated by at least 7 days (Fig. 1). 
All tests were performed in the morning between 0830 and 0900 h 
after an overnight fast. An antecubital venous catheter was placed 
and kept patent by slow saline infusion. The volunteers remained 
recumbent throughout the test. The experiments satisfied the ethical 
precepts of the responsible committee on human experimentation 
and of the Helsinki Declaration. 
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Test 1 (GHRHIGHRH-TRH) 
After a stabilization period of 30 min, the volunteers were given an 
iv bolus of 100 pg GHRH-(l-44) (Somatobiss, Bissendorf Biochemicals, 
Bissendorf bei Hannover, Germany) over 30 s. After 120 min, this pro- 
cedure was repeated. After 150 min, 200 pg TRH (Relefact TRH 200, 
Hoechst, Bad Soden, Germany) were injected iv. Blood samples were 
drawn at intervals of 15 or 30 min from the beginning of the stabilization 
period up to 240 min after starting the test. 
Test 2 (GHRHJArg-TRH) 
One hundred micrograms of GHRH-(l-44) were given iv at 0 min. 
Thirty grams of Arg were administered in 500 mL saline from 120-150 
min, followed by an injection of 200 pg TRH, iv. Blood samples were 
drawn as described in test 1. 
Test 3 (GHRH / GHRH-Arg-TRH) 
One hundred micrograms of GHRH-(l-44) were injected iv at 0 min. 
The volunteers received a second 100~pg GHRH-(l-44) injection after 
120 min, immediately before starting the 30 g Arg infusion (over 30 min). 
Two hundred micrograms of TRH were given iv after 150 min. Blood 
samples were drawn as described in test 1. 
Test 4 (GHRH-Arg-TRH) 
One hundred micrograms of GHRH-(l-44) were administered at 0 
min, immediately followed by an infusion of 30 g Arg over 30 min and 
200 pg TRH, iv, thereafter. Blood samples were drawn 30 min before 
until 120 min after starting the test, at 15- and 30-min intervals. 
Test 5 (TRH) 
Two hundred micrograms of TRH were injected iv at 0 min. Blood 
samples were drawn from 30 min before to 90 min after starting the test, 
at 15- and 30-min intervals. 
Assays 
GH was measured by a commercially available IRMA [immunora- 
diametric assay, Medgenix (Medgenix Diagnostics, Ratingen, Germa- 
ny); intraassay coefficients of variation (CVs), 4.5% and 3.9% for low and 
high concentrations, respectively; interassay CVs, 8.3% and 5.9%). TSH 
was measured as previously described (10). The intraassay CVs were 
5.9% and 7.7% for low and high concentrations, respectively; the inter- 
assay CV was 13%. Serum samples for GH and TSH determinations were 
stored at -20 C until the time of assay. 
Statistical analysis 
All values are given as the mean + SE. For statistical evaluation, 
baseline GH (0 or 120 min) and maximum GH (45 or 165 min) were 
compared by Student’s t test, and significance was corrected using the 
Bonferroni rule. The area under the GH curve (AUC) from O-120 min 
was compared to the AUC from 120 -240 min by ANOVA. The TSH AUC 
was evaluated up to 90 min after TRH injection using ANOVA. If 
ANOVA proved to be significant, further testing with paired Wilcoxon’s 
rank test was performed. The results were considered significant at a 
level of P 5 0.05. 
Results 
No serious side-effects were recorded after GHRH-(1-44) 
or TRH iv bolus injection or during any of the Arg infusions. 
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Minor complaints were transient facial flushing soon after 
GHRH bolus administration and an urge to urinate imme- 
diately after TRH injection, which subsided within 3-5 min. 
Test 1 
After the first GHRH injection, the mean GH concentration 
of eight normal men increased significantly from 0.3 + 0.0 
Fg/L (mean k SE) at 0 min to a maximum of 14.4 ? 3.9 Fg/L 
at 45 min (Fig. 2). Compared to this, the mean GH increase 
after the second GHRH injection at 120 min was significantly 
lower (from 4.5 2 1.6 pg/L to 5.6 2 1.6 after 165 min). The 
AUC of the GH response was also significantly lower (P < 
0.02) after the second stimulation (0.5 +- 0.1 minmg/L VS. 1.2 
2 0.3 after the first GHRH stimulation). 
Test 2 
After Arg-TRH administration, the mean GH concentra- 
tion increased significantly from 2.9 ? 0.8 pg/L at 120 min 
to a maximum of 13.6 t 3.9 pg/L (Fig. 3) after 165 min. There 
were no significant differences between the GH response to 
GHRH injected at 0 min (AUC, 0.9 k 0.2 minmg/L) and that 
to Arg given 120 min after GHRH (AUC, 0.9 k 0.2 minmg/ 
L), as shown in Fig. 3. 
Test 3 
After another GHRH injection, followed by Arg-TRH ad- 
ministration, the mean GH level increased significantly from 
6.3 k 3.0 kg/L at 120 min to a maximum of 30.3 ? 6.8 pg/L 
(Fig. 4) at 165 min. The AUC of the GH increase seen after 
the first GHRH injection at 0 min was 1.2 k 0.3 minmg/L. 
Compared to this, the GH increase after combined GHRH- 
Arg administration (AUC, 1.9 -C 0.4 minmg/L) was signif- 
icantly larger (P < 0.02), as shown in Fig. 4. 
Test 4 
After iv GHRH followed by immediate Arg infusion and 
TRH administration after 30 min, the mean GH concentration 
increased significantly from 0.3 2 0.0 pg/L at 0 min to a 
30 -I GHRH GHRH TRH 
-30 0 30 60 90 120 150 180 210 240 time(min) 
FIG. 2. Test 1 (GHRWGHRH-TRH): mean GH levels before and after 
iv stimulation. Arrows indicate the times of GHRH (0 and 120 min) 
and TRH (150 min) injections. The AUC of the GH response after the 
second GHRH injection was significantly lower than the AUC of the 
first GH increase (P < 0.02). 
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FIG. 3. Test 2 (GHRWArg-TRH): mean GH levels before and after iv 
stimulation. Arrows indicate the times of GHRH (0 min) and TRH 
(150 min) injections. Arg infusion was given after 120 min over 30 
min. There were no significant differences in GH increase after GHRH 
injected at 0 min and that after Arg infusion at 120 min. 
maximum of 46.5 + 11.8 kg/L (Fig. 5) at 60 min. The GH 
response (P < 0.02) to combined GHRH-Arg-TRH stimula- 
tion was significantly lower after previous GHRH injection 
(AUC, 1.9 +- 0.4 minmg/L) than after GHRH-Arg-TRH stim- 
ulation alone (AUC, 3.5 2 0.9 mirrmg/L), as shown in Figs. 
4 and 5. 
Summing up the AUCs of tests 1 and 2 between 120-240 
min gives a result that is still significantly lower (P < 0.05) 
than the AUC of combined GHRH-Arg-TRH stimulation 
after previous GHRH injection (test 3), as shown in Figs. 2-4. 
In test 4, the GHRH/Arg/TRH-stimulated TSH secretion 
(AUC, 537 t 181 minmU/L) was significantly higher (P 5 
0.02) than that after TRH alone (test 5,468 2 151 minmU/L). 
In tests 1,2, and 3 (AUC in test 1,565 + 228 min/mU*L; test 
2, 537 2 192; test 3, 490 k 143), there was no significant 
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FIG. 4. Test 3 (GHRH/GHRH-Arg-TRH): mean GH levels before and 
after iv stimulation. Arrows indicate the times of GHRH (0 and 120 
min) and TRH (150 min) injections. Arg infusion was given after 120 
min over 30 min. Compared to AUC after iv GHRH injection at 0 min, 
GH release after combined GHRH/Arg/TRH stimulation was signif- 
icantly greater (P < 0.02). 
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FIG. 5. Test 4 (GHRH-Arg-TRH): mean GH levels before and after iv 
stimulation. Arrows indicate the times of GHRH (0 min) and TRH (30 
min) injections. Arg infusion was given over 30 min, immediately after 
GHRH stimulation. Mean GH concentrations increased significantly, 
reaching a maximum at 60 min. 
difference in stimulated TSH secretion compared to that after 
TRH alone (test 5). 
Discussion 
The present report confirms that the mean GH response to 
a second GHRH injection is significantly lower than the first 
GH increase. These findings are in agreement with data 
presented by Losa et IZI. (6), who showed that intermittent 
stimulation of GH secretion with 50 pg GHRH-(l-44) within 
2 h as well as continuous stimulation by GHRH infusion over 
2 h result in a decreased GH response in normal subjects. 
Shibasaki et al. (11) and Page et al. (12) described similar 
changes in plasma GH levels in normal men pretreated with 
200 pg GHRH-(l-44). To clarify the mechanism of persistent 
GHRH-induced GH hypersecretion, additional studies dur- 
ing 24-h GHRH infusion were performed (13,14). Continu- 
ous SC infusions of GHRH increased GH peak frequency 
during both the day and the night, but mean GH levels and 
AUC increased only during the daytime hours (14). It was 
speculated that the decrease in nocturnal GH peak amplitude 
and the decreased GH response after short term repeated 
stimulation with GHRH may be due to either a depletion of 
the readily available GH pool or, alternatively, to hypotha- 
lamic somatostatin antagonizing GHRH-stimulated GH se- 
cretion (6, 14). Vance et al. (15) found an augmentation of 
naturally occurring GH pulses during continuous infusion of 
GHRH and concluded that these GH pulses are the result of 
GHRH secretion associated with a diminution or withdrawal 
of somatostatin secretion. Ross et al. (16) showed that GH 
may regulate its own secretion, probably at the hypothalamic 
or pituitary level, via changes in hypothalamic somatostatin 
secretion. The results observed by Shibasaki et al. (11) and 
Ghigo et al. (17) also suggested that a desensitization of 
GHRH receptors in somatotrophs and/or enhanced soma- 
tostatin release induced by an increase in GH levels after a 
previous GHRH injection may be involved in the mechanism 
by which the prior GHRH injection suppresses the GH re- 
sponse to the second GHRH bolus. Arg is known to stimulate 
GH secretion by suppression of hypothalamic somatostatin 
(9). We demonstrated that Arg administered together with 
GHRH led to higher serum GH levels than a single dose of 
GHRH or Arg alone and concluded that the stimulatory 
effect of Arg was mediated by suppression of endogenous 
hypothalamic somatostatin secretion (9). Further support of 
this hypothesis was given by Ghigo et al. in 1990 (18), who 
showed that both Arg and pyridostigmine induce a clear GH 
increase in children with familial short stature by the same 
mechanism, namely suppression of somatostatin release. 
These data in normal adults were confirmed in our study. In 
contrast, Magnan et al. (19) demonstrated a direct effect of 
neostigmine on hypothalamic GHRH release in rams and 
showed a synergistic effect of GHRH and neostigmine on GH 
secretion. These differences from human results are probably 
due to species differences and may be explained by the use 
of a nonmaximal GHRH stimulation dose in rams. Corre- 
sponding to the reports by Page et al. (12) and Ghigo et al. (17), 
we showed that after prior stimulation with GHRH, the 
second GH response (120 min) is not blunted when per- 
formed with Arg. Our findings also demonstrate that de- 
creasing GH responses to a short term repeated GHRH bolus 
can be partially avoided by a combined stimulation with 
GHRH-Arg. The GH response to combined administration of 
GHRH-Arg after previous GHRH stimulation is even higher 
than the sum of the individual GH responses to GHRH only 
and Arg only, showing that Arg administration potentiates 
GH increase even after prior GHRH exposure. Without prior 
GHRH administration, this potentiation was significantly 
higher, which shows that suppression of hypothalamic so- 
matostatin tonus by Arg could only partially restore the 
diminished GH response after prior GHRH stimulation or 
was not complete. This indicates that the decreased GH re- 
sponse after repeated GHRH administration may be partially 
induced by elevated somatostatin tonus and partially by 
exhaustion of the readily releasable GH pool. 
Confirming our observations (9), Merola et al. (20) dem- 
onstrated that Arg infusion potentiates the TSH responsive- 
ness to TRH in healthy subjects by antagonizing the inhib- 
itory effect of somatostatin on TSH secretion (21). Although 
the TSH increase was significantly higher after stimulation in 
test 4 than after TRH alone, there was no significant differ- 
ence between tests 2 and 3, probably due to the small number 
of subjects and to interindividual fluctuations of the TSH 
response. Additionally, a blunting influence of long term 
GHRH stimulation on TRH-stimulated TSH (tests 1, 2, and 
3) cannot be excluded, masking the effect of enhanced so- 
matostatin tonus on stimulated TSH secretion. 
In conclusion, we propose that a decreased GH response 
to repeated GHRH injection may be due to an elevated hy- 
pothalamic somatostatin secretion, which can be suppressed 
by Arg, and to a limitation of the ready available GH pool in 
the human pituitary. 
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